ClinicalTrials.Veeva

Menu
S

Saint Louis University | SLUCare Academic Pavilion - Endocrinology Division Research

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Peginterferon
Selonsertib
Interferon
BMS-986036
Ribavirin
Nortriptyline
GED-0301
BIIB059
Acetaminophen
FLX-787

Parent organization

This site is a part of Saint Louis University

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

22 of 193 total trials

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE)....

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: Litifilimab
Drug: Placebo
Locations recently updated

The primary objective of the study is to evaluate the long-term safety and tolerability BIIB059 (litifilimab) in participants who completed the paren...

Invitation-only
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: BIIB059 (litifilimab)

The primary purpose of this study is to measure the efficacy and safety of efgartigimod intravenously (IV) compared to placebo in participants with A...

Enrolling
Generalized Myasthenia Gravis
Other: Placebo IV
Biological: Efgartigimod IV

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting
NASH - Nonalcoholic Steatohepatitis
Procedure: Liver Biopsy
Drug: MGL-3196
Status recently updated

The purpose of this study is to evaluate the safety of efgartigimod PH20 SC over a longer period of time in adult participants with moderate-to-sever...

Invitation-only
Active, not recruiting
Bullous Pemphigoid
Drug: Prednisone
Biological: efgartigimod PH20 SC

a Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat (an aldosterone synthase inhibitor), administered on a background of a...

Enrolling
Hypertension
Drug: Placebo
Drug: lorundrostat Dose 2

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectom...

Active, not recruiting
Prostatic Neoplasms
Drug: Placebo
Drug: Apalutamide

The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and...

Enrolling
Chronic Kidney Diseases
Type 2 Diabetes Mellitus
Biological: Renal Autologous Cell Therapy (REACT)
Procedure: Sham Comparator

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subje...

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treat...

Enrolling
Diabetic Macular Edema
Drug: Faricimab

The primary efficacy objective of this study is to test the hypothesis that DBS-f stimulation (ON) will slow cognitive and functional progression of...

Active, not recruiting
Alzheimer Disease
Device: DBS-f On
Device: DBS Off

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will stu...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: Rituximab
Drug: Lenalidomide

This multicenter, prospective, interventional trial is designed to assess the outcome of subjects with symptomatic knee osteoarthritis (OA) that are...

Enrolling
Knee Osteoarthritis
Drug: Corticosteroid injection
Device: Embosphere Microspheres

This study evaluates the use of the Human Acellular Vessel (HAV) in adults with vascular trauma below the neck who are undergoing vascular reconstruc...

Active, not recruiting
Trauma
Vascular System Injury
Biological: Human Acellular Vessel (HAV)

The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizur...

Enrolling
Epilepsy
Device: Activa™ PC and Percept™ PC Neurostimulation Systems

This study will evaluate the safety and efficacy of NKTR-255 following CD19-directed chimeric antigen (CAR)-T cell therapy in patients with relapsed...

Enrolling
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Non-Hodgkin Lymphoma
Drug: NKTR-255 at 3.0 μg/kg
Drug: NKTR-255 at 3.0/6.0 μg/kg

The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and i...

Active, not recruiting
Carcinoma, Hepatocellular
Drug: Oral Placebo
Drug: Lenvatinib
Locations recently updated

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Enrolling
Primary Biliary Cirrhosis
Drug: Seladelpar 10 mg Capsule
Drug: Seladelpar 5 mg Capsule

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid...

Active, not recruiting
Primary Biliary Cirrhosis
Drug: Placebo
Drug: Elafibranor 80mg

The primary objective of the study is to demonstrate the non-inferiority of the antibody response in terms of seroconversion rate 28 days after vacci...

Active, not recruiting
Yellow Fever (Healthy Volunteers)
Biological: Yellow fever vaccine (produced on serum-free Vero cells)
Biological: Yellow fever vaccine

Trial sponsors

S
Gilead Sciences logo
Bristol-Myers Squibb (BMS) logo
Celgene logo
National Institutes of Health (NIH) logo
Boehringer Ingelheim logo
T
Bavarian Nordic logo
Pfizer logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems